Rein Therapeutics, Inc. Common Stock RNTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $3.07M+53.6% | $2M+19.0% | $1.68M-60.8% | $4.29M+40.5% | $3.05M-8.1% | ||
| $2.16M+10.2% | $1.96M-48.6% | $3.81M+47.8% | $2.58M+0.9% | $2.56M+3.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | $7.18M0.0% | $7.18M0.0% | $7.18M0.0% | $7.18M-22.4% | ||
| $5.23M-84.0% | $32.66M+495% | $5.49M-20.1% | $6.87M+22.5% | $5.61M-86.9% | ||
| $5.23M-84.0% | $32.66M+495% | $5.49M-20.1% | $6.87M+22.5% | $5.61M-86.9% | ||
| -$5.23M+84.0% | -$32.66M-495% | -$5.49M+20.1% | -$6.87M-22.5% | -$5.61M+86.9% | ||
| -$608K— | —— | -$89K-282% | $49K-54.6% | $108K-60.3% | ||
| —— | -$178K0.0% | -$178K0.0% | -$178K0.0% | -$178K+53.9% | ||
| -$5.84M+81.7% | -$31.97M-473% | -$5.58M+18.2% | -$6.82M-24.0% | -$5.5M+86.6% | ||
| -$0.19+84.4% | -$1.22-481% | -$0.21+25.0% | -$0.28-12.0% | -$0.25+88.6% | ||
| -$0.19+84.4% | -$1.22-481% | -$0.21+25.0% | -$0.28-12.0% | -$0.25+88.6% | ||
| 30.4M+19.3% | 25.4M-3.5% | 26.4M+9.0% | 24.2M+10.4% | 21.9M+22.2% | ||
| 30.4M+19.3% | 25.4M-3.5% | 26.4M+9.0% | 24.2M+10.4% | 21.9M+22.2% | ||
| -$5.84M+81.7% | -$31.99M-473% | -$5.58M+18.3% | -$6.83M-23.9% | -$5.52M+86.5% | ||
| $0+100% | -$36K— | $0+100% | -$24K-177% | $31K— | ||
| $0— | —— | $0-100% | $12K+127% | -$45K-663% | ||
| -$608K— | —— | -$89K-282% | $49K-54.6% | $108K-60.3% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$5.23M+84.0% | -$32.66M-495% | -$5.49M+20.1% | -$6.87M-22.5% | -$5.61M+86.9% | ||
| —— | —— | —— | -$6.87M-22.5% | -$5.61M— | ||
| -$5.23M+84.0% | -$32.66M-495% | -$5.49M+20.1% | -$6.87M-22.5% | -$5.61M+86.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Rein Therapeutics, Inc. Common Stock profitable?
- Rein Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $50.2M over the trailing twelve months.
- What is Rein Therapeutics, Inc. Common Stock's earnings per share?
- Rein Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.90.
- Where does Rein Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Rein Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.